These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Systemic therapy with bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT). Chavan A; Schumann-Binarsch S; Luthe L; Nickau B; Elsässer A; Kühnel T; Geisthoff U; Köhne H Vasa; 2013 Mar; 42(2):106-10. PubMed ID: 23485837 [TBL] [Abstract][Full Text] [Related]
25. Bevacizumab: an option for refractory epistaxis in hereditary haemorrhagic telangiectasia. Amann A; Steiner N; Gunsilius E Wien Klin Wochenschr; 2015 Aug; 127(15-16):631-4. PubMed ID: 25986996 [TBL] [Abstract][Full Text] [Related]
26. Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial. Whitehead KJ; Sautter NB; McWilliams JP; Chakinala MM; Merlo CA; Johnson MH; James M; Everett EM; Clancy MS; Faughnan ME; Oh SP; Olitsky SE; Pyeritz RE; Gossage JR JAMA; 2016 Sep; 316(9):943-51. PubMed ID: 27599329 [TBL] [Abstract][Full Text] [Related]
27. Osteonecrosis after intranasal injection with bevacizumab in treating hereditary hemorrhagic telangiectasia: A case report. Steineger J; Merckoll E; Slåstad JM; Eriksen EF; Heimdal K; Dheyauldeen S Laryngoscope; 2018 Mar; 128(3):593-596. PubMed ID: 28671294 [TBL] [Abstract][Full Text] [Related]
28. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Mitchell A; Adams LA; MacQuillan G; Tibballs J; vanden Driesen R; Delriviere L Liver Transpl; 2008 Feb; 14(2):210-3. PubMed ID: 18236396 [TBL] [Abstract][Full Text] [Related]
29. Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia. Epperla N; Hocking W Clin Med Res; 2015 Mar; 13(1):32-5. PubMed ID: 24667223 [TBL] [Abstract][Full Text] [Related]
30. [Bevacizumab: a new success in hereditary hemorrhagic telangiectasia]. Bennesser Alaoui H; Lehraiki M; Hamaz S; El Attar N; Fakhreddine N; Serraj K Rev Med Interne; 2015 Sep; 36(9):623-5. PubMed ID: 25595875 [TBL] [Abstract][Full Text] [Related]
31. [Bevacizumab in therapy-refractory epistaxis: case report of low-dose antibody therapy for hereditary hemorrhagic telangiectasia]. Rohrmeier C; Kühnel TS HNO; 2012 Nov; 60(11):1003-6. PubMed ID: 22706563 [TBL] [Abstract][Full Text] [Related]
32. [Hereditary hemorrhagic telangiectasia (OslerWeberRendu syndrome) - Part II. Pharmacological therapy and international guidelines for the therapy 2020]. Adam Z; Brančiková D; Romanová G; Pour L; Krejčí M; König J; Nebeský T; Adamová Z; Štork M; Krejčí M; Ševčíková S; Eid M; Sandecká V; Král Z Vnitr Lek; 2021; 67(7):419-424. PubMed ID: 35459360 [TBL] [Abstract][Full Text] [Related]
33. Mobile Mitral and Aortic Valvular Masses in Patients With Hereditary Hemorrhagic Telangiectasia Receiving Intravenous Bevacizumab. Albitar HA; Almodallal Y; Nishimura R; Iyer VN Mayo Clin Proc Innov Qual Outcomes; 2020 Aug; 4(4):460-463. PubMed ID: 32793873 [TBL] [Abstract][Full Text] [Related]
34. Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding. Epperla N; Kapke JT; Karafin M; Friedman KD; Foy P Am J Hematol; 2016 Jun; 91(6):E313-4. PubMed ID: 26994402 [No Abstract] [Full Text] [Related]
36. Intravenous Bevacizumab in Hereditary Hemorrhagic Telangiectasia: A Role That Is Still to Be Defined. Dupuis-Girod S Mayo Clin Proc; 2020 Aug; 95(8):1565-1566. PubMed ID: 32753127 [No Abstract] [Full Text] [Related]
37. Subaortic Membranes in Patients With Hereditary Hemorrhagic Telangiectasia and Liver Vascular Malformations. Kim AS; Henderson KJ; Pawar S; Kim MJ; Punjani S; Pollak JS; Fahey JT; Garcia-Tsao G; Sugeng L; Young LH J Am Heart Assoc; 2020 Oct; 9(20):e016197. PubMed ID: 33054561 [TBL] [Abstract][Full Text] [Related]
38. Iron deficiency anemia related to hereditary hemorrhagic telangiectasia: response to treatment with bevacizumab. Fleagle JM; Bobba RK; Kardinal CG; Freter CE Am J Med Sci; 2012 Mar; 343(3):249-51. PubMed ID: 22227516 [TBL] [Abstract][Full Text] [Related]
39. Successful management of chronic gastrointestinal hemorrhage using bevacizumab in the setting of hereditary hemorrhagic telangiectasia. Sehl ME; M Gruber T; McWilliams JP; Marder VJ Am J Hematol; 2015 Jun; 90(6):561-3. PubMed ID: 25677911 [No Abstract] [Full Text] [Related]
40. Bevacizumab to Treat Cholangiopathy in Hereditary Hemorrhagic Telangiectasia: Be Cautious: A Case Report. Maestraggi Q; Bouattour M; Toquet S; Jaussaud R; Kianmanesh R; Durand F; Servettaz A Medicine (Baltimore); 2015 Nov; 94(46):e1966. PubMed ID: 26579805 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]